GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on January 17, 2024, reports transaction notifications for GSK Plc. The filing details share transactions executed on January 15, 2024, by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions relate to the re-investment of dividends paid on January 11, 2024, under the Company's Deferred Annual Bonus Plan and Performance Share Plan.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports specific share transaction data:
- Transaction Date: January 15, 2024
- Transaction Type: Increase in notional interest or acquisition of shares via dividend re-investment.
- Share Prices:
- Ordinary Shares (London Stock Exchange): £15.5640
- American Depositary Shares (New York Stock Exchange): $39.6400
- Participants: 13 PDMRs, including CEO Emma Walmsley, Non-Executive Director Dr. Hal Barron, and various Senior Vice Presidents.
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. The reported changes are limited to the increase in individual notional shareholdings resulting from the dividend re-investment mechanism.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Key Facts for Investor Verification
- Verify the dividend payment date of January 11, 2024, and the subsequent re-investment execution on January 15, 2024.
- Confirm the share prices of £15.5640 (GBP) and $39.6400 (USD) against market data for January 15, 2024.
- Note that CEO Emma Walmsley participated in two separate transactions: one under the Deferred Annual Bonus Plan (2,327 Ordinary Shares) and one under the Performance Share Plan (4,947.304 Ordinary Shares).
- Confirm that all transactions were executed on the London Stock Exchange (XLON) or New York Stock Exchange (XNYS) as disclosed.